Abstract
We describe a single-center pediatric experience with 1 mg/kg/wk cidofovir without probenecid in 7 children with BK virus-associated hemorrhagic cystitis. Clinical improvement was observed in all cases, without adverse events, although significant reduction of urinary viral load was observed 2 weeks after the end of cidofovir in 5 out of 6 patients who completed the treatment.
MeSH terms
-
Adolescent
-
Antiviral Agents / administration & dosage*
-
BK Virus / isolation & purification*
-
Child
-
Child, Preschool
-
Cidofovir
-
Cystitis / drug therapy
-
Cystitis / virology
-
Cytosine / administration & dosage
-
Cytosine / analogs & derivatives*
-
Drug Administration Schedule
-
Hematopoietic Stem Cell Transplantation
-
Hemorrhage / drug therapy
-
Hemorrhage / virology
-
Humans
-
Organophosphonates / administration & dosage*
-
Polyomavirus Infections / drug therapy*
-
Polyomavirus Infections / virology
-
Probenecid / administration & dosage
-
Tumor Virus Infections / drug therapy*
-
Tumor Virus Infections / virology
Substances
-
Antiviral Agents
-
Organophosphonates
-
Cytosine
-
Cidofovir
-
Probenecid